skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy

Abstract

Purpose/Objectives: Evidence from the management of oligometastases with stereotactic body radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We have previously identified a multigene expression index for tumor radiosensitivity (RSI) with validation in multiple independent cohorts. In this study, we assessed RSI in liver metastases and assessed our clinical outcomes after SBRT based on primary histology. Methods and Materials: Patients were identified from our prospective, observational protocol. The previously tested RSI 10 gene assay was run on samples and calculated using the published algorithm. An independent cohort of 33 patients with 38 liver metastases treated with SBRT was used for clinical correlation. Results: A total of 372 unique metastatic liver lesions were identified for inclusion from our prospective, institutional metadata pool. The most common primary histologies for liver metastases were colorectal adenocarcinoma (n=314, 84.4%), breast adenocarcinoma (n=12, 3.2%), and pancreas neuroendocrine (n=11, 3%). There were significant differences in RSI of liver metastases based on histology. The median RSIs for liver metastases in descending order of radioresistance were gastrointestinal stromal tumor (0.57), melanoma (0.53), colorectal neuroendocrine (0.46), pancreas neuroendocrine (0.44), colorectal adenocarcinoma (0.43), breast adenocarcinoma (0.35), lung adenocarcinoma (0.31), pancreas adenocarcinoma (0.27), anal squamous cell cancer (0.22), andmore » small intestine neuroendocrine (0.21) (P<.0001). The 12-month and 24-month Kaplan-Meier rates of local control (LC) for colorectal lesions from the independent clinical cohort were 79% and 59%, compared with 100% for noncolorectal lesions (P=.019), respectively. Conclusions: In this analysis, we found significant differences based on primary histology. This study suggests that primary histology may be an important factor to consider in SBRT radiation dose selection.« less

Authors:
;  [1];  [2]; ;  [3];  [4]; ; ; ;  [1];  [3];  [1]
  1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (United States)
  2. Department of Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (United States)
  3. Department of Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (United States)
  4. Department of Biostastistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (United States)
Publication Date:
OSTI Identifier:
22648758
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 95; Journal Issue: 5; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; HISTOLOGY; LIVER; MAMMARY GLANDS; NEOPLASMS; PANCREAS; RADIATION DOSES; RADIOSENSITIVITY; RADIOTHERAPY

Citation Formats

Ahmed, Kamran A., Caudell, Jimmy J., El-Haddad, Ghassan, Berglund, Anders E., Welsh, Eric A., Yue, Binglin, Hoffe, Sarah E., Naghavi, Arash O., Abuodeh, Yazan A., Frakes, Jessica M., Eschrich, Steven A., and Torres-Roca, Javier F., E-mail: Javier.torresroca@moffitt.org. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. United States: N. p., 2016. Web. doi:10.1016/J.IJROBP.2016.03.050.
Ahmed, Kamran A., Caudell, Jimmy J., El-Haddad, Ghassan, Berglund, Anders E., Welsh, Eric A., Yue, Binglin, Hoffe, Sarah E., Naghavi, Arash O., Abuodeh, Yazan A., Frakes, Jessica M., Eschrich, Steven A., & Torres-Roca, Javier F., E-mail: Javier.torresroca@moffitt.org. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. United States. doi:10.1016/J.IJROBP.2016.03.050.
Ahmed, Kamran A., Caudell, Jimmy J., El-Haddad, Ghassan, Berglund, Anders E., Welsh, Eric A., Yue, Binglin, Hoffe, Sarah E., Naghavi, Arash O., Abuodeh, Yazan A., Frakes, Jessica M., Eschrich, Steven A., and Torres-Roca, Javier F., E-mail: Javier.torresroca@moffitt.org. Mon . "Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy". United States. doi:10.1016/J.IJROBP.2016.03.050.
@article{osti_22648758,
title = {Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy},
author = {Ahmed, Kamran A. and Caudell, Jimmy J. and El-Haddad, Ghassan and Berglund, Anders E. and Welsh, Eric A. and Yue, Binglin and Hoffe, Sarah E. and Naghavi, Arash O. and Abuodeh, Yazan A. and Frakes, Jessica M. and Eschrich, Steven A. and Torres-Roca, Javier F., E-mail: Javier.torresroca@moffitt.org},
abstractNote = {Purpose/Objectives: Evidence from the management of oligometastases with stereotactic body radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We have previously identified a multigene expression index for tumor radiosensitivity (RSI) with validation in multiple independent cohorts. In this study, we assessed RSI in liver metastases and assessed our clinical outcomes after SBRT based on primary histology. Methods and Materials: Patients were identified from our prospective, observational protocol. The previously tested RSI 10 gene assay was run on samples and calculated using the published algorithm. An independent cohort of 33 patients with 38 liver metastases treated with SBRT was used for clinical correlation. Results: A total of 372 unique metastatic liver lesions were identified for inclusion from our prospective, institutional metadata pool. The most common primary histologies for liver metastases were colorectal adenocarcinoma (n=314, 84.4%), breast adenocarcinoma (n=12, 3.2%), and pancreas neuroendocrine (n=11, 3%). There were significant differences in RSI of liver metastases based on histology. The median RSIs for liver metastases in descending order of radioresistance were gastrointestinal stromal tumor (0.57), melanoma (0.53), colorectal neuroendocrine (0.46), pancreas neuroendocrine (0.44), colorectal adenocarcinoma (0.43), breast adenocarcinoma (0.35), lung adenocarcinoma (0.31), pancreas adenocarcinoma (0.27), anal squamous cell cancer (0.22), and small intestine neuroendocrine (0.21) (P<.0001). The 12-month and 24-month Kaplan-Meier rates of local control (LC) for colorectal lesions from the independent clinical cohort were 79% and 59%, compared with 100% for noncolorectal lesions (P=.019), respectively. Conclusions: In this analysis, we found significant differences based on primary histology. This study suggests that primary histology may be an important factor to consider in SBRT radiation dose selection.},
doi = {10.1016/J.IJROBP.2016.03.050},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 5,
volume = 95,
place = {United States},
year = {Mon Aug 01 00:00:00 EDT 2016},
month = {Mon Aug 01 00:00:00 EDT 2016}
}